New Treatment for Breakthrough Cancer Pain Accepted for Use in Scotland

19-Jan-2011 - United Kingdom

Archimedes Pharma Ltd announced the decision by the Scottish Medicines Consortium (SMC) to accept PecFent® (fentanyl pectin nasal spray) for use within NHS Scotland.  PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Following the SMC clinical effectiveness and health economic review of the product, PecFent has been accepted for use in Scotland for breakthrough cancer pain (BTCP) patients unsuitable for short-acting oral opioids or as an alternative to other fentanyl preparations.

Jeffrey H. Buchalter, President and Chief Executive Officer of Archimedes Pharma, commented: “This is a key outcome from one of Europe’s foremost Health Technology Assessment agencies.  The SMC’s balanced review of PecFent’s clinical effectiveness and health economic value supports Archimedes’ belief that PecFent provides a real opportunity for patients, for healthcare professionals, and for payors to improve the management of breakthrough cancer pain and the cost effectiveness of that management. We welcome the decision by the SMC to accept PecFent for use within the NHS in Scotland.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances